Lipoxin A4 mediates aortic contraction via rhoa/rho kinase, endothelial dysfunction and reactive oxygen species

Journal of Vascular Research

Volumn 51, Issue 6, 2014, Pages 407-417

  Wenceslau, Camilla F ^a   Mccarthy, Cameron Grant ^a   Szasz, Theodora ^a   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aorta; Contractile responses; Endothelial dysfunction; Lipoxin A4

Indexed keywords

ACETYLCHOLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; LIPOXIN A; MYOSIN LIGHT CHAIN; PHENYLEPHRINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REGULATOR PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ANTIOXIDANT; LIPOXIN; LIPOXIN A(4) RECEPTOR, RAT; LIPOXIN RECEPTOR; PROTEIN KINASE INHIBITOR; PTGS2 PROTEIN, RAT; RHOA PROTEIN, HUMAN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; AORTA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; LIPOXINS; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, LIPOXIN; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84924274399     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000371490     Document Type: Article

References (27)

1. Serhan CN, Hamberg M, Samuelsson B: Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984; 81: 5335-5339.
2. Kantarci A, Van Dyke TE: Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 2003; 14: 4-12.
3. Brezinski DA, Nesto RW, Serhan CN: Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 1992; 86: 56-63.
4. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C: FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 2010; 24: 4240-4249.
5. Spite M, Serhan CN: Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107: 1170-1184.
6. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM: Aspirin-Triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost 2007; 97: 88-98.
7. Wu Y, Zhai H, Wang Y, Li L, Wu J, Wang F, Sun S, Yao S, Shang Y: Aspirin-Triggered lipoxin A4 attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase. Neurochem Res 2012; 37: 1690-1696.
8. von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL: Aspirin-Triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 2004; 110: 1320-1325.
9. Feuerstein G, Siren AL: Mesenteric vascular responses to i.v. administration of lipoxin A4 and lipoxin B4 in the conscious rat. FEBS Lett 1988; 232: 51-55.
10. Wenceslau CF, Rossoni LV: Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/cSRC pathway. J Hypertens 2014; 32: 542-554.
11. Heymes C, Habib A, Yang D, Mathieu E, Marotte F, Samuel J, Boulanger CM: Cyclo-oxygenase-1 and-2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 2000; 131: 804-810.
12. Virdis A, Colucci R, Fornai M, Duranti E, Giannarelli C, Bernardini N, Segnani C, Ippolito C, Antonioli L, Blandizzi C, Taddei S, Salvetti A, Del Tacca M: Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension 2007; 49: 679-686.
13. Wenceslau CF, Davel AP, Xavier FE, Rossoni LV: Long-Term ouabain treatment impairs vascular function in resistance arteries. J Vasc Res 2011; 48: 316-326.
14. Cattaneo F, Parisi M, Ammendola R: Distinct signaling cascades elicited by different formyl Peptide receptor 2 (FPR2) agonists. Int J Mol Sci 2013; 14: 7193-7230.
15. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC: Mitochondrial damage-Associated molecular patterns and vascular function. Eur Heart J 2014; 35: 1172-1177.
16. Le Y, Murphy PM, Wang JM: Formyl-peptide receptors revisited. Trends Immunol 2002; 23: 541-548.
17. Bode SM, Kuhn M, Forstermann U: Chemotactic peptide FMLP contracts human coronary arteries via cyclooxygenase products. Am J Physiol 1990; 258:H848-H853.
18. Keitoku M, Kohzuki M, Katoh H, Funakoshi M, Suzuki S, Takeuchi M, Karibe A, Horiguchi S, Watanabe J, Satoh S, Nose M, Abe K, Okayama H, Shirato K: FMLP actions and its binding sites in isolated human coronary arteries. J Mol Cell Cardiol 1997; 29: 881-894.
19. Wenceslau CF, McCarthy CG, Goulopoulou S, Szasz T, NeSmith EG, Webb RC: Mitochondrial-derived N-formyl peptides: novel links between trauma, vascular collapse and sepsis. Med Hypotheses 2013; 81: 532-535.
20. Boulanger CM, Vanhoutte PM: Interleukin-2 causes endothelium-dependent contractions to arachidonic acid. Hypertension 1993; 21: 289-293.
21. Webb RC: Smooth muscle contraction and relaxation. Adv Physiol Educ 2003; 27: 201-206.
22. McMahon B, Godson C: Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol 2004; 286:F189-F201.
23. Vila E, Salaices M: Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005; 288:H1016-H1021.
24. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens 2003; 12: 181-187.
25. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 2004; 44: 248-252.
26. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
27. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, Brandes RP: Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51: 211-217.